People · Operator

Jason Gray

Named in public records as an officer, director or promoter · active 2010–2024 · Other Technology, Other Health Care

3
Companies
4
Filings
$3.2M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Archeio Technologies, LLCOther TechnologySeed$1.7M$8.8M
Tensegrity Technologies IncOther Health CarePre-Seed$1.3M$30.3M2010
Maxim Biomedical, Inc.Other Health CarePre-Seed$225K$1.0M2024
Operator network

Jason Gray at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Chetan Chouhan · 2 companies · 1 sharedChetan ChouhanRex Womble · 2 companies · 1 sharedRex WombleKenneth Aboussie · 1 companies · 1 sharedKenneth AboussieJohn Kevin Friedman · 1 companies · 1 sharedJohn Kevin Friedm…Joseph Kevin Miller · 1 companies · 1 sharedJoseph Kevin Mill…Michael Kevin Boennighausen · 1 companies · 1 sharedMichael Kevin Boe…Neal Kevin Eigler · 1 companies · 1 sharedNeal Kevin EiglerSue Ann Latterman · 1 companies · 1 sharedSue Ann LattermanJonathan Maa · 1 companies · 1 sharedJonathan MaaJuehn-Shin Maa · 1 companies · 1 sharedJuehn-Shin MaaArcheio Technologies, LLC · $1.7M raisedArcheio Technologies,…Tensegrity Technologies Inc · $1.3M raisedTensegrity Technologi…Maxim Biomedical, Inc. · $0.2M raisedMaxim Biomedical, Inc.Jason GrayJG
Jason Gray Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Jason Gray on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Chetan Chouhan12
Rex Womble12
Jonathan Maa11
Juehn-Shin Maa11
John Kevin Friedman11
Sue Ann Latterman11
Joseph Kevin Miller11
Michael Kevin Boennighausen11
Neal Kevin Eigler11
Kenneth Aboussie11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.